Volume 26 - Issue 11 - November 2018

Jak pathway
Carlos G. Wambier, MD, PhD, and Brett A. King, MD, PhD
JAK inhibitors appear to be effective for the treatment of AD, and this class of medications will influence the current paradigm of AD management.
Eileen Koutnik-Fotopoulos, Contributing Editor
psoriasis case
Gina Mangin, MPAS, PA-C and Christopher Crotty, MD
Dr Lipoff
Section Editor, Benjamin Barankin, MD, FRCPC
asymptomatic blister front view
Joyce Y. Cheng, MD, MHS, and Philip R. Cohen, MD